ArticleBMJ public health2024
Ten-year (2009-2019) epidemiological study of head and neck, salivary glands and upper aerodigestive tract cancers, and overall survival outcomes in the Northern Territory of Australia.
Article in BMJ public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Head and neck, salivary glands and aerodigestive tract cancers (HNACs) rank sixth in cancer incidence in Australia, posing significant public health and economic challenges. However, data on HNACs in the Northern Territory (NT) are lacking, crucial for healthcare planning. Objective: This study aims to analyse HNACs epidemiology, risk factors and survival outcomes in the NT, focusing on Indigenous and non-Indigenous Australians. Methods: We conducted a retrospective analysis (2009-2019) of HNACs cases from the NT Cancer Registry. Ethically approved, the study assessed incidence, mortality, risk factors and survival across ethnic populations. Results: Of 612 potential cases, 524 were analysed, with 35.5% identifying as Aboriginal or Torres Strait Islanders. Predominantly affecting males (median age: 62 years), HNACs showed an age-standardised incidence of 21.9 per 100 000, with stable trends. The 5-year survival rate was 39.6%, notably lower in Indigenous Australians (25%) and remote areas (18%) vs the national average (68%). Oropharyngeal malignancies were common (36% survival). High-risk behaviours such as alcohol use (73%) and smoking (91%) prevailed. Most patients (73%) presented with advanced disease (stages III-IV), with one-third offered palliative care at diagnosis. P16-negative tumours predominated, with increasing P16-positive cases in non-Indigenous patients. Conclusion: HNACs survival rates in the NT are significantly lower than the national average, especially among Indigenous Australians and remote residents. Targeted interventions are needed to improve service planning and delivery, considering identified risk factors and cultural sensitivities, and promoting Indigenous participation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.